You will receive blinatumomab for up to 5 cycles. You may continue to receive ponatinib for as long as the doctor thinks it is in your best interest. You will no longer be able to take the study drug(s) if the disease gets worse, if intolerable side effects occur, the study doctor thinks it is in your best interest to stop taking part in the study, the study is cancelled, or if you are unable to follow study directions.